Effects of alendronate on bone turnover markers in early postmenopausal women

Chinese Medical Journal (Taipei)

Volumn 61, Issue 10, 1998, Pages 568-576

  Yang, Tzay Shing ^a   Tsan, Shun Hwa ^b   Chen, Chuen Rong ^b   Chang, Sheng Ping ^b   Yuan, Chiou Chung ^b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

Alendronate; Bone turnover markers; Menopause; Osteoporosis

Indexed keywords

ALENDRONIC ACID;

ADULT; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; RANDOMIZED CONTROLLED TRIAL; URINARY EXCRETION;

ALENDRONATE; ALKALINE PHOSPHATASE; AMINO ACIDS; BONE AND BONES; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE;

EID: 0031729028     PISSN: 05781337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Papapoulos SE. The role of bisphosphonates in the prevention and treatment of osteoporosis. Am J Med 1993;95(Suppl 5A):48-52.
2. Vitte C, Fleisch H, Guenther HL. Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology 1996;137:2324-32.
3. Fleisch H. Bisphosphonates: pharmacology. Semin Arthritis Rheum 1994;23:261-2.
4. Delmas PD. Biochemical markers for the assessment of bone turnover. In: Riggs BL, Melton LJ, eds. Osteoporosis: Etiology, Diagnosis and Management. Philadelphia: Lippincott Raven Publishers, 1995:319-33.
5. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Rodriguez J, et al. Effect of oral Fosamax (alendronate) on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. New Engl J Med 1995;333: 1437-43.
6. Chesnut CH 3rd, McClung MR, Ensrud KE, Bell NH, Genant HK, Harris ST, et al. Fosamax (alendronate) treatment of the postmenopausal osteoporotic woman: effect of multiple dosages on bone mass and bone remodeling. Am J Med 1995;99:144-52.
7. Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, et al. Fracture intervention trial research group. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535-41.
8. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to Fosamax (alendronate) treatment. J Clin Endocrinol Metab 1994;79:1693-700.
9. Harris ST, Gertz BJ, Genant HK. The effect of short term treatment with Fosamax (alendronate) on vertebral density and biochemical markers of bone remodeling in early postmenopausal women. J Clin Endocrinol Metab 1993;76: 1399-406.
10. Adami S, Passeri M, Ortolani S, Broggini M, Carratelli L, Caruso I, et al. Effects of oral Fosamax (alendronate) and intranasal salmon calcitonin on bone mass and biochemical markers of bone turnover in postmenopausal women with osteoporosis. Bone 1995;17:383-90.
11. Azuma Y, Chokki M, Ohta T, Kiyoki M. Effects of alendronate on plasma calcium levels, urinary calcium excretion, and bone resorption markers in normal rats: comparison with elcatonin synthetic eel calcitonin. Endocrinology 1996;137:2586-92.
12. Matts JP, Lachin JM. Properties of permuted-block randomization in clinical trials. Control Clin Trials 1988;9:327-44.
13. Seyedin SM, Rosen DM. Matrix proteins of the skeleton. Curr Opin Cell Biol 1990;2:914-9.
14. Delmas PD, Gineyts E, Bertholin A, Garnero P, Marchand F. Immunoassay of pyridinoline cross-link excretion in normal adults and in Paget's disease. J Bone Min Res 1993;8:643-8.
15. Johansen J, Riis BJ, Delmas PD, Christiansen C. Plasma BGP: an indicator of spontaneous bone loss and of the effect of estrogen treatment on postmenopausal women. J Clin Invest 1988;18:191-5.
16. Slemenda C, Hui SL, Longcope C, Johnston CC. Sex steroids and bone mass: a study of changes about the time of menopause. J Clin Invest 1987;80:1261-9.